O
KPTI icon

OrbiMed’s Karyopharm Therapeutics KPTI Stock Holding History

OrbiMed’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-41,460
Closed -$11.9M – 153
2019
Q4 		$11.9M Sell
41,460
-29,600
-42% -$6.42M 0.17% 77
2019
Q3 		$10.3M Sell
71,060
-138,838
-66% -$18.8M 0.19% 78
2019
Q2 		$18.9M Buy
+209,898
New +$16.9M 0.29% 72

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

OrbiMed's KPTI Position: Q1 2020 in Review

OrbiMed sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 41,460 shares — an estimated $11.9M sold.

OrbiMed first reported a position in KPTI in Q2 2019 and held it in 3 quarters. The position peaked at $18.9M in Q2 2019. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

  • OrbiMed reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
  • OrbiMed sold 41,460 Karyopharm Therapeutics shares in Q1 2020, an estimated $11.9M.
  • OrbiMed first reported a position in Karyopharm Therapeutics in Q2 2019 and held it in 3 quarters.
  • OrbiMed's Karyopharm Therapeutics position peaked at $18.9M in Q2 2019.
  • 136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.